Dorine W Swinkels

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2893502/publications.pdf

Version: 2024-02-01

298	20,508	10351	12558
papers	citations	72 h-index	132 g-index

304	304	304	23141
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Investigating the Molecular Mechanisms of Renal Hepcidin Induction and Protection upon Hemoglobin-Induced Acute Kidney Injury. International Journal of Molecular Sciences, 2022, 23, 1352.	1.8	4
2	Kidney tubule iron loading in experimental focal segmental glomerulosclerosis. Scientific Reports, 2022, 12, 1199.	1.6	6
3	Transferrin Saturation/Hepcidin Ratio Discriminates TMPRSS6-Related Iron Refractory Iron Deficiency Anemia from Patients with Multi-Causal Iron Deficiency Anemia. International Journal of Molecular Sciences, 2022, 23, 1917.	1.8	4
4	Ferritin-guided iron supplementation in whole blood donors: optimal dosage, donor response, return and efficacy (FORTE)â€"a randomised controlled trial protocol. BMJ Open, 2022, 12, e056316.	0.8	6
5	Hepcidin response to interval running exercise is not affected by oral contraceptive phase in enduranceâ€trained women. Scandinavian Journal of Medicine and Science in Sports, 2021, 31, 643-652.	1.3	7
6	Iron deficiency. Lancet, The, 2021, 397, 233-248.	6.3	396
7	Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome. Leukemia, 2021, 35, 1745-1750.	3.3	15
8	Iron homeostasis during anemia of inflammation: a prospective study of patients with tuberculosis. Blood, 2021, 138, 1293-1303.	0.6	20
9	Inflammation can increase hepcidin in HFEâ€hereditary hemochromatosis. Clinical Case Reports (discontinued), 2021, 9, e04114.	0.2	1
10	Absorption of nonheme iron during gastric acid suppression in patients with hereditary hemochromatosis and healthy controls. American Journal of Physiology - Renal Physiology, 2021, 320, G1105-G1110.	1.6	2
11	Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney International, 2021, 99, 1280-1295.	2.6	103
12	The EHA Research Roadmap: Anemias. HemaSphere, 2021, 5, e607.	1.2	7
13	Differentiating iron-loading anemias using a newly developed and analytically validated ELISA for human serum erythroferrone. PLoS ONE, 2021, 16, e0254851.	1.1	5
14	The critical roles of iron during the journey from fetus to adolescent: Developmental aspects of iron homeostasis. Blood Reviews, 2021, 50, 100866.	2.8	20
15	Genetic Diagnosis in Hereditary Hemochromatosis: Discovering and Understanding the Biological Relevance of Variants. Clinical Chemistry, 2021, 67, 1324-1341.	1.5	5
16	Comparative Evaluation of Sucrosomial Iron and Iron Oxide Nanoparticles as Oral Supplements in Iron Deficiency Anemia in Piglets. International Journal of Molecular Sciences, 2021, 22, 9930.	1.8	7
17	Novel concepts in red blood cell clearance. Current Opinion in Hematology, 2021, 28, 438-444.	1.2	5
18	Optimizing hepcidin measurement with a proficiency test framework and standardization improvement. Clinical Chemistry and Laboratory Medicine, 2021, 59, 315-323.	1.4	23

#	Article	IF	Citations
19	Streptococcus gallolyticus Increases Expression and Activity of Aryl Hydrocarbon Receptor-Dependent CYP1 Biotransformation Capacity in Colorectal Epithelial Cells. Frontiers in Cellular and Infection Microbiology, 2021, 11, 740704.	1.8	11
20	Innovative oral sucrosomial ferric pyrophosphate-based supplementation rescues suckling piglets from iron deficiency anemia similarly to commonly used parenteral therapy with iron dextran. Annals of Animal Science, 2021, 21, 524-541.	0.6	0
21	Protocol of the Healthy Brain Study: An accessible resource for understanding the human brain and how it dynamically and individually operates in its bio-social context. PLoS ONE, 2021, 16, e0260952.	1.1	8
22	Malaria early in the first pregnancy: Potential impact of iron status. Clinical Nutrition, 2020, 39, 204-214.	2.3	15
23	The multifaceted role of iron in renal health and disease. Nature Reviews Nephrology, 2020, 16, 77-98.	4.1	167
24	Standardized serum hepcidin values in Dutch children: Set point relative to body iron changes during childhood. Pediatric Blood and Cancer, 2020, 67, e28038.	0.8	16
25	Menopause Delays the Typical Recovery of Pre-Exercise Hepcidin Levels after High-Intensity Interval Running Exercise in Endurance-Trained Women. Nutrients, 2020, 12, 3866.	1.7	3
26	A possible role for hepcidin in the detection of iron deficiency in severely anaemic HIV-infected patients in Malawi. PLoS ONE, 2020, 15, e0218694.	1.1	4
27	Effect of Oral Supplementation of Healthy Pregnant Sows with Sucrosomial Ferric Pyrophosphate on Maternal Iron Status and Hepatic Iron Stores in Newborn Piglets. Animals, 2020, 10, 1113.	1.0	10
28	Title is missing!. , 2020, 15, e0218694.		0
29	Title is missing!. , 2020, 15, e0218694.		0
30	Title is missing!. , 2020, 15, e0218694.		0
31	Title is missing!. , 2020, 15, e0218694.		0
32	Title is missing!. , 2020, 15, e0218694.		0
33	Title is missing!. , 2020, 15, e0218694.		0
34	Unraveling Hepcidin Plasma Protein Binding: Evidence from Peritoneal Equilibration Testing. Pharmaceuticals, 2019, 12, 123.	1.7	8
35	Twenty Years of Ferroportin Disease: A Review or An Update of Published Clinical, Biochemical, Molecular, and Functional Features. Pharmaceuticals, 2019, 12, 132.	1.7	36
36	Chronic Adherence to a Ketogenic Diet Modifies Iron Metabolism in Elite Athletes. Medicine and Science in Sports and Exercise, 2019, 51, 548-555.	0.2	41

#	Article	IF	Citations
37	Hypoxia attenuates inflammation-induced hepcidin synthesis during experimental human endotoxemia. Haematologica, 2019, 104, e230-e232.	1.7	7
38	First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis. PLoS ONE, 2019, 14, e0212023.	1.1	41
39	Iron handling by the human kidney: glomerular filtration and tubular reabsorption both contribute to urinary iron excretion. American Journal of Physiology - Renal Physiology, 2019, 316, F606-F614.	1.3	22
40	Association of anemia with health-related quality of life and survival: a large population-based cohort study. Haematologica, 2019, 104, 468-476.	1.7	91
41	Provisional standardization of hepcidin assays: creating a traceability chain with a primary reference material, candidate reference method and a commutable secondary reference material. Clinical Chemistry and Laboratory Medicine, 2019, 57, 864-872.	1.4	39
42	Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function. European Journal of Heart Failure, 2018, 20, 910-919.	2.9	225
43	Therapeutic recommendations in HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype. Hepatology International, 2018, 12, 83-86.	1.9	41
44	A Stepwise Procedure to Define a Data Collection Framework for a Clinical Biobank. Biopreservation and Biobanking, 2018, 16, 138-147.	0.5	8
45	Utility of zinc protoporphyrin in management of whole blood donors. Transfusion, 2018, 58, 692-700.	0.8	3
46	Definition of Iron Deficiency Based on the Gold Standard of Bone Marrow Iron Staining in Heart Failure Patients. Circulation: Heart Failure, 2018, 11, e004519.	1.6	147
47	Sustained plasma hepcidin suppression and iron elevation by Anticalinâ€derived hepcidin antagonist in cynomolgus monkey. British Journal of Pharmacology, 2018, 175, 1054-1065.	2.7	30
48	Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes. Haematologica, 2018, 103, 69-79.	1.7	35
49	Loss-of-function ferroportin disease: novel mechanistic insights and unanswered questions. Haematologica, 2018, 103, 1753-1755.	1.7	3
50	An intensified training schedule in recreational male runners is associated with increases in erythropoiesis and inflammation and a net reduction in plasma hepcidin. American Journal of Clinical Nutrition, 2018, 108, 1324-1333.	2.2	22
51	Tubular iron deposition and iron handling proteins in human healthy kidney and chronic kidney disease. Scientific Reports, 2018, 8, 9353.	1.6	74
52	The phenotypic spectrum of germline YARS2 variants: from isolated sideroblastic anemia to mitochondrial myopathy, lactic acidosis and sideroblastic anemia 2. Haematologica, 2018, 103, 2008-2015.	1.7	19
53	Role of the Complement System in Chronic Central Serous Chorioretinopathy. JAMA Ophthalmology, 2018, 136, 1128.	1.4	49
54	Endogenous hepcidin synthesis protects the distal nephron against hemin and hemoglobin mediated necroptosis. Cell Death and Disease, 2018, 9, 550.	2.7	20

#	Article	IF	Citations
55	Effects of Weekly Iron and Folic Acid Supplements on Malaria Risk in Nulliparous Women in Burkina Faso: A Periconceptional, Double-Blind, Randomized Controlled Noninferiority Trial. Journal of Infectious Diseases, 2018, 218, 1099-1109.	1.9	18
56	Towards an External Quality Assessment for Next Generation Sequencing in the Diagnosis of Rare Inherited Anaemias. Blood, 2018, 132, 4936-4936.	0.6	1
57	The Radboud Biobank: A Central Facility for Disease-Based Biobanks to Optimise Use and Distribution of Biomaterial for Scientific Research in the Radboud University Medical Center, Nijmegen. Open Journal of Bioresources, 2018, 5, .	1.5	16
58	Elevated Labile Plasma Iron (LPI) Levels in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Are Associated with Decreased Quality of Life and Reduced Survival. Blood, 2018, 132, 4392-4392.	0.6	0
59	Cohort Profile: The Nijmegen Biomedical Study (NBS). International Journal of Epidemiology, 2017, 46, dyw268.	0.9	30
60	Factors influencing the post-exercise hepcidin-25 response in elite athletes. European Journal of Applied Physiology, 2017, 117, 1233-1239.	1.2	47
61	Prediction of human iron bioavailability using rapid c-ELISAs for human plasma hepcidin. Clinical Chemistry and Laboratory Medicine, 2017, 55, 1186-1192.	1.4	6
62	Oral iron supplementation: Potential implications for the gut microbiome and metabolome in patients with CKD. Hemodialysis International, 2017, 21, S28-S36.	0.4	45
63	A rare splice donor mutation in the haptoglobin gene associates with blood lipid levels and coronary artery disease. Human Molecular Genetics, 2017, 26, 2364-2376.	1.4	17
64	Interleukin-6 and Hepcidin Levels during Hormone-Deplete and Hormone-Replete Phases of an Oral Contraceptive Cycle: A Pilot Study. Annals of Nutrition and Metabolism, 2017, 70, 100-105.	1.0	9
65	<scp>EPO</scp> and hepcidin plasma concentrations in blood donors and Î²â€thalassemia intermedia are not related to commercially tested plasma <scp>ERFE</scp> concentrations. American Journal of Hematology, 2017, 92, E29-E31.	2.0	10
66	Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematology,the, 2017, 4, e524-e533.	2.2	276
67	Serum ferritin and risk for newâ€onset heart failure and cardiovascular events in the community. European Journal of Heart Failure, 2017, 19, 348-356.	2.9	38
68	Pharmacokinetics of Ferric Pyrophosphate Citrate, a Novel Iron Salt, Administered Intravenously to Healthy Volunteers. Journal of Clinical Pharmacology, 2017, 57, 312-320.	1.0	16
69	Dietary hemoglobin rescues young piglets from severe iron deficiency anemia: Duodenal expression profile of genes involved in heme iron absorption. PLoS ONE, 2017, 12, e0181117.	1.1	34
70	Molecular Diagnostic Testing in Clinical Chemistry. , 2017, , 131-154.		0
71	Meta-GWAS and Meta-Analysis of Exome Array Studies Do Not Reveal Genetic Determinants of Serum Hepcidin. PLoS ONE, 2016, 11, e0166628.	1.1	2
72	Course of iron parameters in HFEâ€hemochromatosis patients during initial treatment with erythrocytapheresis compared to phlebotomy. Journal of Clinical Apheresis, 2016, 31, 564-570.	0.7	10

#	Article	IF	Citations
73	Seven days of high carbohydrate ingestion does not attenuate post-exercise IL-6 and hepcidin levels. European Journal of Applied Physiology, 2016, 116, 1715-1724.	1.2	15
74	Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders. Haematologica, 2016, 101, 38-45.	1.7	74
75	VariantASGR1Associated with a Reduced Risk of Coronary Artery Disease. New England Journal of Medicine, 2016, 374, 2131-2141.	13.9	137
76	Renal Handling of Circulating and Renal-Synthesized Hepcidin and Its Protective Effects against Hemoglobinâ€“Mediated Kidney Injury. Journal of the American Society of Nephrology: JASN, 2016, 27, 2720-2732.	3.0	50
77	Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease. Nature Genetics, 2016, 48, 634-639.	9.4	214
78	Toward Worldwide Hepcidin Assay Harmonization: Identification of a Commutable Secondary Reference Material. Clinical Chemistry, 2016, 62, 993-1001.	1.5	73
79	Hepcidin in the diagnosis of iron disorders. Blood, 2016, 127, 2809-2813.	0.6	309
80	Pleiotropic Analysis of Lung Cancer and Blood Triglycerides. Journal of the National Cancer Institute, 2016, 108, djw167.	3.0	17
81	Cardiac Hepcidin Expression Associates with Injury Independent of Iron. American Journal of Nephrology, 2016, 44, 368-378.	1.4	18
82	Iron refractory iron deficiency anemia: a heterogeneous disease that is not always iron refractory. American Journal of Hematology, 2016, 91, E482-E490.	2.0	28
83	Key-interventions derived from three evidence based guidelines for management and follow-up of patients with HFE haemochromatosis. BMC Health Services Research, 2016, 16, 573.	0.9	6
84	Catalytic iron and acute kidney injury. American Journal of Physiology - Renal Physiology, 2016, 311, F871-F876.	1.3	32
85	The donation interval of 56 days requires extension to 180 days for whole blood donors to recover from changes in iron metabolism. Blood, 2016, 128, 2185-2188.	0.6	44
86	Hyperferritinemia and iron metabolism in Gaucher disease: Potential pathophysiological implications. Blood Reviews, 2016, 30, 431-437.	2.8	22
87	Underestimation of hepcidin concentration by time of flight mass spectrometry and competitive ELISA in hepcidin p.Gly71Asp heterozygotes. Clinical Chemistry and Laboratory Medicine, 2016, 54, e173-6.	1.4	0
88	EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH). European Journal of Human Genetics, 2016, 24, 479-495.	1.4	73
89	Elevated Labile Plasma Iron Levels (LPI) and Increased Oxidative Stress Are Associated with Red Blood Cell Transfusions in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Subtitle: from the European Leukemianet MDS Registry. Blood, 2016, 128, 4327-4327.	0.6	1
90	Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood, 2015, 126, 1981-1989.	0.6	372

#	Article	IF	Citations
91	Congenital sideroblastic anemia due to mutations in the mitochondrial HSP70 homologue HSPA9. Blood, 2015, 126, 2734-2738.	0.6	78
92	Low dietary iron intake restrains the intestinal inflammatory response and pathology of enteric infection by foodâ€borne bacterial pathogens. European Journal of Immunology, 2015, 45, 2553-2567.	1.6	56
93	Urinary Hepcidin Levels in Iron-Deficient and Iron-Supplemented Piglets Correlate with Hepcidin Hepatic mRNA and Serum Levels and with Body Iron Status. PLoS ONE, 2015, 10, e0136695.	1.1	15
94	The Growth Attainment, Hematological, Iron Status and Inflammatory Profile of Guatemalan Juvenile End-Stage Renal Disease Patients. PLoS ONE, 2015, 10, e0140062.	1.1	3
95	Timing of post-exercise carbohydrate ingestion: influence on IL-6 and hepcidin responses. European Journal of Applied Physiology, 2015, 115, 2215-2222.	1.2	24
96	Differences in the erythropoiesis-hepcidin-iron store axis between hemoglobin H disease and Â-thalassemia intermedia. Haematologica, 2015, 100, e169-e171.	1.7	24
97	Inter-ethnic differences in genetic variants within the transmembrane protease, serine 6 (TMPRSS6) gene associated with iron status indicators: a systematic review with meta-analyses. Genes and Nutrition, 2015, 10, 442.	1.2	27
98	The aetiology of anaemia during pregnancy: a study to evaluate the contribution of iron deficiency and common infections in pregnant Ugandan women. Public Health Nutrition, 2015, 18, 1423-1435.	1.1	24
99	Common Variants and Haplotypes in the TF, TNF-Î±, and TMPRSS6 Genes Are Associated with Iron Status in a Female Black South African Population. Journal of Nutrition, 2015, 145, 945-953.	1.3	18
100	Correlates of Hepcidin and NTBI according to HFE Status in Patients Referred to a Liver Centre. Acta Haematologica, 2015, 133, 155-161.	0.7	7
101	Microcytic anaemia with low transferrin saturation, increased serum hepcidin and nonâ€synonymous <scp>TMPRSS</scp>6 variants: not always ironâ€refractory iron deficiency anaemia. British Journal of Haematology, 2015, 169, 150-151.	1.2	3
102	Iron and hepcidin as risk factors in atherosclerosis: what do the genes say?. BMC Genetics, 2015, 16, 79.	2.7	23
103	Acute dietary carbohydrate manipulation and the subsequent inflammatory and hepcidin responses to exercise. European Journal of Applied Physiology, 2015, 115, 2521-2530.	1.2	51
104	The quality of hereditary haemochromatosis guidelines: A comparative analysis. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, 205-214.	0.7	11
105	Oral contraception does not alter typical post-exercise interleukin-6 and hepcidin levels in females. Journal of Science and Medicine in Sport, 2015, 18, 8-12.	0.6	23
106	Iron fortification adversely affects the gut microbiome, increases pathogen abundance and induces intestinal inflammation in Kenyan infants. Gut, 2015, 64, 731-742.	6.1	477
107	Microbial Metabolism Shifts Towards an Adverse Profile with Supplementary Iron in the TIM-2 In vitro Model of the Human Colon. Frontiers in Microbiology, 2015, 6, 1481.	1.5	55
108	Labile Plasma Iron (LPI) Is a Clinical Indicator of Overt Iron Overload in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) from the European Leukemianet MDS Registry. Blood, 2015, 126, 2865-2865.	0.6	3

#	Article	IF	Citations
109	A Phase I Study Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of the Hepcidin Antagonist PRS-080#022. Results from a Randomized, Placebo Controlled, Double-Blind Study Following Single Administration to Healthy Subjectsa. Blood, 2015, 126, 536-536.	0.6	12
110	The Donation Interval of 56 Days Requires Extension to 180 Days for Whole Blood Donors to Recover from Disturbances in Iron Homeostasis. Blood, 2015, 126, 774-774.	0.6	0
111	Left Ventricular Mass in Dialysis Patients, Determinants and Relation with Outcome. Results from the COnvective TRansport STudy (CONTRAST). PLoS ONE, 2014, 9, e84587.	1.1	24
112	Iron Status and the Acute Post-Exercise Hepcidin Response in Athletes. PLoS ONE, 2014, 9, e93002.	1.1	118
113	Iron-Induced Virulence of Salmonella enterica Serovar Typhimurium at the Intestinal Epithelial Interface Can Be Suppressed by Carvacrol. Antimicrobial Agents and Chemotherapy, 2014, 58, 1664-1670.	1.4	12
114	The effect of iron loading and iron chelation on the innate immune response and subclinical organ injury during human endotoxemia: a randomized trial. Haematologica, 2014, 99, 579-587.	1.7	19
115	Serum hepcidin measured by immunochemical and mass-spectrometric methods and their correlation with iron status indicators in healthy children aged 0.5â€“3 y. Pediatric Research, 2014, 76, 409-414.	1.1	26
116	Reference intervals of complete blood count constituents are highly correlated to waist circumference: Should obese patients have their own â€œnormal values?â€• American Journal of Hematology, 2014, 89, 671-677.	2.0	54
117	Serum Hepcidin Is Associated With Presence of Plaque in Postmenopausal Women of a General Population. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 446-456.	1.1	40
118	The value of soluble transferrin receptor and hepcidin in the assessment of iron status in children with cystic fibrosis. Journal of Cystic Fibrosis, 2014, 13, 639-644.	0.3	15
119	Influence of post-exercise hypoxic exposure on hepcidin response in athletes. European Journal of Applied Physiology, 2014, 114, 951-959.	1.2	24
120	Xâ€linked sideroblastic anemia due to ALAS2 intron 1 enhancer element GATAâ€binding site mutations. American Journal of Hematology, 2014, 89, 315-319.	2.0	39
121	Novel loci affecting iron homeostasis and their effects in individuals at risk for hemochromatosis. Nature Communications, 2014, 5, 4926.	5.8	192
122	Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin. Leukemia and Lymphoma, 2014, 55, 270-275.	0.6	43
123	Nutritional iron turned inside out: intestinal stress from a gut microbial perspective. FEMS Microbiology Reviews, 2014, 38, 1202-1234.	3.9	219
124	Conventional and novel peripheral blood iron markers compared against bone marrow in Malawian children. Journal of Clinical Pathology, 2014, 67, 717-723.	1.0	26
125	A seven day running training period increases basal urinary hepcidin levels as compared to cycling. Journal of the International Society of Sports Nutrition, 2014, 11, 14.	1.7	20
126	Engineered Human Lipocalin as an Antibody Mimetic: Application to Analysis of the Small Peptide Hormone Hepcidin. Clinical Chemistry, 2014, 60, 897-899.	1.5	8

#	Article	IF	Citations
127	Practice guidelines for the diagnosis and management of microcytic anemias due to genetic disorders of iron metabolism or heme synthesis. Blood, 2014, 123, 3873-3886.	0.6	64
128	Acute hypoxic exercise does not alter post-exercise iron metabolism in moderately trained endurance athletes. European Journal of Applied Physiology, 2014, 114, 2183-2191.	1.2	22
129	The importance of the general practitioner as an information source for patients with hereditary haemochromatosis. Patient Education and Counseling, 2014, 96, 86-92.	1.0	11
130	Serum hepcidin following autologous hematopoietic cell transplantation: an illustration of the interplay of iron status, erythropoiesis and inflammation. Haematologica, 2014, 99, e35-e37.	1.7	6
131	Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans. Blood, 2014, 124, 2643-2646.	0.6	96
132	Hematologic parameters predicting a response to oral iron therapy in chronic inflammation. Haematologica, 2014, 99, e171-e173.	1.7	30
133	International Comparison Study of Toxic Iron Assays in Patients with Iron Overload Disorders. Blood, 2014, 124, 4033-4033.	0.6	0
134	Tubular reabsorption and local production of urine hepcidin-25. BMC Nephrology, 2013, 14, 70.	0.8	27
135	High prevalence of subclinical iron deficiency in whole blood donors not deferred for low hemoglobin. Transfusion, 2013, 53, 1670-1677.	0.8	65
136	The iron link between malaria and invasive non-typhoid Salmonella infections. Trends in Parasitology, 2013, 29, 220-227.	1.5	31
137	High levels of soluble serum hemojuvelin in patients with congenital dyserythropoietic anemia type I. European Journal of Haematology, 2013, 90, 31-36.	1.1	14
138	SMIM1 underlies the Vel blood group and influences red blood cell traits. Nature Genetics, 2013, 45, 542-545.	9.4	96
139	Iron metabolism in the pathogenesis of iron-induced kidney injury. Nature Reviews Nephrology, 2013, 9, 385-398.	4.1	126
140	Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients. Nephrology Dialysis Transplantation, 2013, 28, 3062-3071.	0.4	67
141	Associations of common variants inHFEandTMPRSS6with iron parameters are independent of serum hepcidin in a general population: a replication study. Journal of Medical Genetics, 2013, 50, 593-598.	1.5	34
142	Low Hepcidin Levels in Severely Anemic Malawian Children with High Incidence of Infectious Diseases and Bone Marrow Iron Deficiency. PLoS ONE, 2013, 8, e78964.	1.1	35
143	The iron regulatory hormone hepcidin is decreased in pregnancy: a prospective longitudinal study. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1395-401.	1.4	78
144	Relevance of dietary iron intake and bioavailability in the management of HFE hemochromatosis: a systematic review. American Journal of Clinical Nutrition, 2013, 98, 468-479.	2.2	29

#	Article	IF	Citations
145	Plasma hepcidin levels and anemia in old age. The Leiden 85-Plus Study. Haematologica, 2013, 98, 448-454.	1.7	47
146	The effect of frequent whole blood donation on ferritin, hepcidin, and subclinical atherosclerosis. Transfusion, 2013, 53, 1468-1474.	0.8	11
147	Diurnal Rhythm rather than Dietary Iron Mediates Daily Hepcidin Variations. Clinical Chemistry, 2013, 59, 527-535.	1.5	67
148	Effect of Exercise Modality and Intensity on Postexercise Interleukin-6 and Hepcidin Levels. International Journal of Sport Nutrition and Exercise Metabolism, 2013, 23, 178-186.	1.0	55
149	Adaptation of iron transport and metabolism to acute high-altitude hypoxia in mountaineers. Hepatology, 2013, 58, 2153-2162.	3.6	71
150	Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1. Haematologica, 2013, 98, 420-423.	1.7	51
151	Inverse Relationship of Serum Hepcidin Levels with CD4 Cell Counts in HIV-Infected Patients Selected from an Indonesian Prospective Cohort Study. PLoS ONE, 2013, 8, e79904.	1.1	29
152	Iron Supplementation in Suckling Piglets: How to Correct Iron Deficiency Anemia without Affecting Plasma Hepcidin Levels. PLoS ONE, 2013, 8, e64022.	1.1	50
153	Improved Mass Spectrometry Assay For Plasma Hepcidin: Detection and Characterization of a Novel Hepcidin Isoform. PLoS ONE, 2013, 8, e75518.	1.1	76
154	Status of Selected Ironâ€Status Biomarkers in Juvenile Endâ€•Stage Renal Disease in a Guatemalan Context: Comparative Aspects by Mode of Dialysis. FASEB Journal, 2013, 27, 223.8.	0.2	0
155	Acute Acetaminophen Intoxication Leads to Hepatic Iron Loading by Decreased Hepcidin Synthesis. Toxicological Sciences, 2012, 129, 225-233.	1.4	17
156	CSK regulatory polymorphism is associated with systemic lupus erythematosus and influences B-cell signaling and activation. Nature Genetics, 2012, 44, 1227-1230.	9.4	110
157	Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Chronic Cardiorenal Failure is Correlated with Endogenous Erythropoietin Levels and Decreases in Response to Low-Dose Erythropoietin Treatment. Kidney and Blood Pressure Research, 2012, 36, 344-354.	0.9	18
158	The Effects of Acute Exercise Bouts on Hepcidin in Women. International Journal of Sport Nutrition and Exercise Metabolism, 2012, 22, 79-88.	1.0	69
159	Genome-wide meta-analysis of common variant differences between men and women. Human Molecular Genetics, 2012, 21, 4805-4815.	1.4	33
160	Second round robin for plasma hepcidin methods: First steps toward harmonization. American Journal of Hematology, 2012, 87, 977-983.	2.0	81
161	Intra-individual variability of serum hepcidin-25 in haemodialysis patients using mass spectrometry and ELISA. Nephrology Dialysis Transplantation, 2012, 27, 3923-3929.	0.4	20
162	Candidate Gene Sequencing of SLC11A2 and TMPRSS6 in a Family with Severe Anaemia: Common SNPs, Rare Haplotypes, No Causative Mutation. PLoS ONE, 2012, 7, e35015.	1.1	21

#	Article	IF	Citations
163	Hepcidin-25 in Chronic Hemodialysis Patients Is Related to Residual Kidney Function and Not to Treatment with Erythropoiesis Stimulating Agents. PLoS ONE, 2012, 7, e39783.	1.1	47
164	The effects of carbohydrate ingestion during endurance running on post-exercise inflammation and hepcidin levels. European Journal of Applied Physiology, 2012, 112, 1889-1898.	1.2	47
165	Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. Journal of Clinical Investigation, 2012, 122, 368-382.	3.9	183
166	Single and Repeated Dose First-in-Human Study with the Anti-Hepcidin Spiegelmer Nox-H94.. Blood, 2012, 120, 2342-2342.	0.6	4
167	Randomized Double Blind Placebo Controlled PK/PD Study On the Effects of a Single Intravenous Dose of the Anti-Hepcidin Spiegelmer Nox-H94 On Serum Iron During Experimental Human Endotoxemia. Blood, 2012, 120, 3452-3452.	0.6	3
168	Iron Availability Increases the Pathogenic Potential of Salmonella Typhimurium and Other Enteric Pathogens at the Intestinal Epithelial Interface. PLoS ONE, 2012, 7, e29968.	1.1	154
169	Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood, 2011, 117, e218-e225.	0.6	246
170	Hepcidin in Human Iron Disorders: Diagnostic Implications. Clinical Chemistry, 2011, 57, 1650-1669.	1.5	216
171	Determinants of Red Cell Distribution Width (RDW) in Cardiorenal Patients: RDW is Not Related to Erythropoietin Resistance. Journal of Cardiac Failure, 2011, 17, 626-633.	0.7	60
172	Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 568-575.	1.1	78
173	Inflammation-induced hepcidin-25 is associated with the development of anemia in septic patients: an observational study. Critical Care, 2011, 15, R9.	2.5	41
174	Novel observations in hereditary hemochromatosis: potential implications for clinical strategies. Haematologica, 2011, 96, 485-488.	1.7	8
175	Mass Spectrometry Analysis of Hepcidin Peptides in Experimental Mouse Models. PLoS ONE, 2011, 6, e16762.	1.1	25
176	Application and validation of a diagnostic algorithm for the atherogenic apoB dyslipoproteinemias. European Journal of Clinical Investigation, 2011, 41, 423-433.	1.7	11
177	Growth differentiation factor 15 in patients with congenital dyserythropoietic anaemia (CDA) type II. Journal of Molecular Medicine, 2011, 89, 811-816.	1.7	42
178	Hepcidin in anemia of chronic heart failure. American Journal of Hematology, 2011, 86, 107-109.	2.0	29
179	Hepcidin and hemoglobin content parameters in the diagnosis of iron deficiency in rheumatoid arthritis patients with anemia. Arthritis and Rheumatism, 2011, 63, 3672-3680.	6.7	105
180	Clinical Importance of Streptococcus gallolyticus Infection Among Colorectal Cancer Patients: Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2011, 53, 870-878.	2.9	310

#	Article	IF	Citations
181	Serum Hepcidin and Macrophage Iron Correlate With MCP-1 Release and Vascular Damage in Patients With Metabolic Syndrome Alterations. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 683-690.	1.1	78
182	Surface-Affinity Profiling To Identify Host-Pathogen Interactions. Infection and Immunity, 2011, 79, 4777-4783.	1.0	26
183	A toxic shot from the hip. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 353-354.	0.9	10
184	Reproducibility of and Correspondence among Different Hepcidin Forms in Blood and Urine and Their Relationships to Iron Status in Healthy, Male Guatemalan Volunteers Observed over 9 Weeks. Annals of Nutrition and Metabolism, 2011, 58, 158-166.	1.0	1
185	Novel Clues on the Specific Association of Streptococcus gallolyticus subsp gallolyticus With Colorectal Cancer. Journal of Infectious Diseases, 2011, 203, 1101-1109.	1.9	137
186	Iron Homeostasis in Mother and Child during Placental Malaria Infection. American Journal of Tropical Medicine and Hygiene, 2011, 84, 148-151.	0.6	25
187	Reply to S. Zucker. Journal of Clinical Oncology, 2011, 29, e43-e43.	0.8	0
188	Hepcidin in malaria superinfection: can findings be translated to humans?. Nature Medicine, 2011, 17, 1341-1341.	15.2	4
189	Increased exposure to bacterial antigen RpL7/L12 in early stage colorectal cancer patients. Cancer, 2010, 116, 4014-4022.	2.0	44
190	Recent advances in the understanding of iron overload in sideroblastic myelodysplastic syndrome. British Journal of Haematology, 2010, 149, 322-333.	1.2	28
191	Genetic Variants in Toll-Like Receptors Are Not Associated with Rheumatoid Arthritis Susceptibility or Anti-Tumour Necrosis Factor Treatment Outcome. PLoS ONE, 2010, 5, e14326.	1.1	24
192	Hepcidinâ€25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patientsâ€. European Journal of Heart Failure, 2010, 12, 943-950.	2.9	67
193	Serum Iron Parameters, HFE C282Y Genotype, and Cognitive Performance in Older Adults: Results From the FACIT Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2010, 65A, 1312-1321.	1.7	27
194	Anemia in Hodgkin's Lymphoma: The Role of Interleukin-6 and Hepcidin. Journal of Clinical Oncology, 2010, 28, 2538-2543.	0.8	86
195	Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate. Nephrology Dialysis Transplantation, 2010, 25, 848-853.	0.4	99
196	Immunochemical and Mass-Spectrometryâ€"Based Serum Hepcidin Assays for Iron Metabolism Disorders. Clinical Chemistry, 2010, 56, 1570-1579.	1.5	190
197	Hemochromatosis (HFE) genotype and atherosclerosis: Increased susceptibility to iron-induced vascular damage in C282Y carriers?. Atherosclerosis, 2010, 211, 520-525.	0.4	12
198	Increased serum hepcidin and alterations in blood iron parameters associated with asymptomatic P. falciparum and P. vivax malaria. Haematologica, 2010, 95, 1068-1074.	1.7	92

#	Article	IF	Citations
199	Regulation of serum hepcidin levels in sickle cell disease. Haematologica, 2009, 94, 885-887.	1.7	31
200	Time-course analysis of serum hepcidin, iron and cytokines in a C282Y homozygous patient with Schnitzler's syndrome treated with IL-1 receptor antagonist. Haematologica, 2009, 94, 1297-1300.	1.7	23
201	A Novel Immunological Assay for Hepcidin Quantification in Human Serum. PLoS ONE, 2009, 4, e4581.	1.1	72
202	Surface-Exposed Histone-Like Protein A Modulates Adherence of Streptococcus gallolyticus to Colon Adenocarcinoma Cells. Infection and Immunity, 2009, 77, 5519-5527.	1.0	40
203	Hepcidin Serum Levels and Resistance to Recombinant Human Erythropoietin Therapy in Haemodialysis Patients. Acta Haematologica, 2009, 122, 226-229.	0.7	41
204	Training Surface and Intensity. Medicine and Science in Sports and Exercise, 2009, 41, 1138-1145.	0.2	95
205	The Metabolic Syndrome and Its Traits as Risk Factors for Subclinical Atherosclerosis. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2893-2899.	1.8	53
206	Mannoseâ€Binding Lectin Is a Critical Factor in Systemic Complement Activation during Meningococcal Septic Shock. Clinical Infectious Diseases, 2009, 49, 1380-1386.	2.9	22
207	Plasma hepcidin concentrations significantly predict interindividual variation in iron absorption in healthy men. American Journal of Clinical Nutrition, 2009, 89, 1088-1091.	2.2	66
208	Hepcidin suppression and defective iron recycling account for dysregulation of iron homeostasis in heme oxygenaseâ€1 deficiency. Journal of Cellular and Molecular Medicine, 2009, 13, 3091-3102.	1.6	37
209	Haematologic data, iron parameters and molecular findings in two new cases of ironâ€refractory iron deficiency anaemia. European Journal of Haematology, 2009, 83, 595-602.	1.1	33
210	Hepcidin Levels in Acute Kidney Injury Following Cardiopulmonary Bypass Grafting. American Journal of Kidney Diseases, 2009, 54, 979.	2.1	5
211	Cumulative effects of consecutive running sessions on hemolysis, inflammation and hepcidin activity. European Journal of Applied Physiology, 2009, 106, 51-59.	1.2	81
212	Mild increases in serum hepcidin and interleukinâ€6 concentrations impair iron incorporation in haemoglobin during an experimental human malaria infection. British Journal of Haematology, 2009, 145, 657-664.	1.2	66
213	Highâ€sensitive radioimmunoassay for human serum hepcidin. British Journal of Haematology, 2009, 146, 317-325.	1.2	58
214	(Pre)analytical imprecision, between-subject variability, and daily variations in serum and urine hepcidin: Implications for clinical studies. Analytical Biochemistry, 2009, 389, 124-129.	1.1	113
215	Severity of iron overload of proband determines serum ferritin levels in families with HFE-related hemochromatosis: The HEmochromatosis FAmily Study. Journal of Hepatology, 2009, 50, 174-183.	1.8	22
216	Assessment of Urinary Concentrations of Hepcidin Provides Novel Insight into Disturbances in Iron Homeostasis during Malarial Infection. Journal of Infectious Diseases, 2009, 199, 253-262.	1.9	82

#	Article	IF	Citations
217	Hepcidin levels in patients with renal disease. Kidney International, 2009, 76, 680.	2.6	4
218	Hepcidin in Obese Children as a Potential Mediator of the Association between Obesity and Iron Deficiency. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 5102-5107.	1.8	164
219	Discrepant Results of Serum Creatinine and Cystatin C as a Clue to Urine Leakage After Renal Transplantation. Transplantation, 2009, 88, 596-597.	0.5	6
220	Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica, 2009, 94, 1748-1752.	1.7	161
221	Effects of Exercise on Hepcidin Response and Iron Metabolism during Recovery. International Journal of Sport Nutrition and Exercise Metabolism, 2009, 19, 583-597.	1.0	119
222	Serum Ferritin Levels Are Associated with Vascular Damage in Patients with Nonalcoholic Fatty Liver Disease.. Blood, 2009, 114, 5098-5098.	0.6	0
223	Anemia in Hodgkin Lymphoma: The Role of Interleukin-6 and Hepcidin.. Blood, 2009, 114, 3656-3656.	0.6	2
224	Shedding & shaving: Disclosure of proteomic expressions on a bacterial face. Proteomics, 2008, 8, 1415-1428.	1.3	104
225	Immunoproteomics: From biomarker discovery to diagnostic applications. Proteomics - Clinical Applications, 2008, 2, 167-180.	0.8	51
226	Secretion of bioactive hepcidin-25 by liver cells correlates with its gene transcription and points towards synergism between iron and inflammation signaling pathways. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2008, 1784, 2029-2037.	1.1	29
227	Many sequence variants affecting diversity of adult human height. Nature Genetics, 2008, 40, 609-615.	9.4	615
228	Common variants on chromosome 5p12 confer susceptibility to estrogen receptorâ€“positive breast cancer. Nature Genetics, 2008, 40, 703-706.	9.4	412
229	Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nature Genetics, 2008, 40, 1307-1312.	9.4	377
230	Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nature Genetics, 2008, 40, 281-283.	9.4	357
231	Serum hepcidin levels are innately low in HFEâ€related haemochromatosis but differ between C282Yâ€homozygotes with elevated and normal ferritin levels. British Journal of Haematology, 2008, 142, 979-985.	1.2	81
232	Hepcidin in the management of patients with mild non-hemochromatotic iron overload: Fact or fiction?. Journal of Hepatology, 2008, 49, 680-685.	1.8	23
233	Regulation of hepcidin: Insights from biochemical analyses on human serum samples. Blood Cells, Molecules, and Diseases, 2008, 40, 339-346.	0.6	102
234	A novel (Leu183Pro-)mutation in the HFE-gene co-inherited with the Cys282Tyr mutation in two unrelated Dutch hemochromatosis patients. Blood Cells, Molecules, and Diseases, 2008, 40, 334-338.	0.6	10

#	Article	IF	Citations
235	Low serum levels of prohepcidin, but not hepcidin-25, are related to anemia in familial amyloidosis TTR V30M. Blood Cells, Molecules, and Diseases, 2008, 41, 175-178.	0.6	6
236	Blood donation, body iron status and carotid intima-media thickness. Atherosclerosis, 2008, 196, 856-862.	0.4	24
237	Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease?. Nephrology Dialysis Transplantation, 2008, 23, 2450-2453.	0.4	71
238	Hepcidin: from discovery to differential diagnosis. Haematologica, 2008, 93, 90-97.	1.7	266
239	Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I. Blood, 2008, 112, 5241-5244.	0.6	125
240	Advances in Quantitative Hepcidin Measurements by Time-of-Flight Mass Spectrometry. PLoS ONE, 2008, 3, e2706.	1.1	176
241	An Insight into the Relationships between Hepcidin, Anemia, Infections and Inflammatory Cytokines in Pediatric Refugees: A Cross-Sectional Study. PLoS ONE, 2008, 3, e4030.	1.1	73
242	Results of the First International Round Robin for the Quantification of Urinary and Plasma Hepcidin: Need for Standardization. Blood, 2008, 112, 120-120.	0.6	7
243	Erythroid Activity, Transfusion Iron Overload, and Hepcidin Levels in Patients with Myelodysplastic Syndrome. Blood, 2008, 112, 2676-2676.	0.6	7
244	High Levels of Growth Differentiation Factor 15 in Patients with Congenital Dyserythtopoietic Anemia Type I. Blood, 2008, 112, 3456-3456.	0.6	0
245	Determinants for Iron Overload-Related Disease in Siblings of Probands with Clinically Detected HFE Hereditary Hemochromatosis: The Hemochromatosis Family Study.. Blood, 2008, 112, 1857-1857.	0.6	0
246	Nitric Oxide Does Not Contribute to Inflammation-Induced Hypoferremia in Humans. Acta Haematologica, 2007, 118, 149-152.	0.7	0
247	Effect of the new HJV-L165X mutation on penetrance of HFE. Blood, 2007, 109, 5525-5526.	0.6	26
248	Mass Spectrometryâ€“Based Hepcidin Measurements in Serum and Urine: Analytical Aspects and Clinical Implications. Clinical Chemistry, 2007, 53, 620-628.	1.5	202
249	Shotgun immunoproteomics to identify disease-associated bacterial antigens: Application to human colon cancer. Proteomics - Clinical Applications, 2007, 1, 429-434.	0.8	15
250	Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nature Genetics, 2007, 39, 631-637.	9.4	818
251	Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nature Genetics, 2007, 39, 977-983.	9.4	670
252	Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptorâ€“positive breast cancer. Nature Genetics, 2007, 39, 865-869.	9.4	774

#	Article	IF	Citations
253	Gene Expression Analysis for the Prediction of Recurrence in Patients with Primary Ta Urothelial Cell Carcinoma. European Urology, 2007, 51, 416-423.	0.9	25
254	Bladder cancer diagnosis and recurrence prognosis: Comparison of markers with emphasis on survivin. Clinica Chimica Acta, 2006, 368, 20-32.	0.5	31
255	Serum non-transferrin-bound iron and low-density lipoprotein oxidation in heterozygous hemochromatosis. Biochemical and Biophysical Research Communications, 2006, 345, 371-376.	1.0	7
256	Polymorphisms in the E-cadherin (CDH1) gene promoter and the risk of bladder cancer. European Journal of Cancer, 2006, 42, 3219-3227.	1.3	22
257	Proteomic inventory of â€œAnchorlessâ€•proteins on the colon adenocarcinoma cell surface. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2006, 1764, 1607-1617.	1.1	14
258	Bromide as a marker to measure adherence to drug therapy. European Journal of Clinical Pharmacology, 2006, 62, 285-290.	0.8	5
259	Prediction of recurrence in Ta urothelial cell carcinoma by real-time quantitative PCR analysis: A microarray validation study. International Journal of Cancer, 2006, 119, 1915-1919.	2.3	18
260	Profiling the humoral immune response in colon cancer patients: Diagnostic antigens fromStreptococcus bovis. International Journal of Cancer, 2006, 119, 2127-2135.	2.3	91
261	Survivin and MKI67 mRNA Expression in Bladder Washings of Patients with Superficial Urothelial Cell Carcinoma Correlate with Tumor Stage and Grade but Do Not Predict Tumor Recurrence. Clinical Chemistry, 2006, 52, 1440-1442.	1.5	5
262	Hereditary Hemochromatosis: Genetic Complexity and New Diagnostic Approaches. Clinical Chemistry, 2006, 52, 950-968.	1.5	96
263	Thyroid Function and Prevalence of Anti-Thyroperoxidase Antibodies in a Population with Borderline Sufficient Iodine Intake: Influences of Age and Sex. Clinical Chemistry, 2006, 52, 104-111.	1.5	199
264	Novel urine hepcidin assay by mass spectrometry. Blood, 2005, 106, 3268-3270.	0.6	125
265	Results of an international round robin for the quantification of serum non-transferrin-bound iron: Need for defining standardization and a clinically relevant isoform. Analytical Biochemistry, 2005, 341, 241-250.	1.1	93
266	Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Laboratory Investigation, 2005, 85, 154-159.	1.7	482
267	CDC91L1 (PIG-U) mRNA expression in urothelial cell carcinomas. International Journal of Cancer, 2005, 116, 282-284.	2.3	7
268	Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood, 2005, 106, 1864-1866.	0.6	459
269	Serum ferritin levels are increased in patients with glomerular diseases and proteinuria. Nephrology Dialysis Transplantation, 2004, 19, 2754-2760.	0.4	34
270	Preeclampsia and the C282Y Mutation in the Hemochromatosis (HFE) Gene. Clinical Chemistry, 2004, 50, 973-974.	1.5	6

#	Article	IF	Citations
271	Survivin mRNA Copy Number in Bladder Washings Predicts Tumor Recurrence in Patients with Superficial Urothelial Cell Carcinomas. Clinical Chemistry, 2004, 50, 1425-1428.	1.5	44
272	Preterm neonates with nephrocalcinosis: natural course and renal function. Pediatric Nephrology, 2003, 18, 1102-1108.	0.9	43
273	Vitamin and homocysteine status of mothers and infants and the risk of nonsyndromic orofacial clefts. American Journal of Obstetrics and Gynecology, 2003, 189, 1155-1160.	0.7	73
274	Maternal myo-inositol, glucose, and zinc status is associated with the risk of offspring with spina bifida. American Journal of Obstetrics and Gynecology, 2003, 189, 1713-1719.	0.7	94
275	PCR-Restriction Fragment Length Polymorphism Method to Detect the X/Y Polymorphism in the Promoter Site of the Mannose-binding Lectin Gene. Clinical Chemistry, 2003, 49, 1557-1558.	1.5	11
276	Effects of Blood-Processing Protocols on Cell-free DNA Quantification in Plasma. Clinical Chemistry, 2003, 49, 525-526.	1.5	93
277	Is serum cystatin C the marker of choice to predict glomerular filtration rate in paediatric patients?. Annals of Clinical Biochemistry, 2003, 40, 60-64.	0.8	30
278	Hemolysis, Elevated Liver Enzymes, and Low Platelet Count (HELLP) Syndrome as a Complication of Preeclampsia in Pregnant Women Increases the Amount of Cell-free Fetal and Maternal DNA in Maternal Plasma and Serum. Clinical Chemistry, 2002, 48, 650-653.	1.5	103
279	Rapid genotyping of single nucleotide polymorphisms using novel minor groove binding DNA oligonucleotides (MGB probes). Human Mutation, 2002, 19, 554-559.	1.1	124
280	DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Research, 2002, 62, 2695-8.	0.4	484
281	Nutrient-dense foods and exercise in frail elderly: effects on B vitamins, homocysteine, methylmalonic acid, and neuropsychological functioning. American Journal of Clinical Nutrition, 2001, 73, 338-346.	2.2	52
282	New technique for diagnosis and monitoring of alcaptonuria: quantification of homogentisic acid in urine with mid-infrared spectrometry. Analytica Chimica Acta, 2001, 429, 287-292.	2.6	19
283	The impact of calcium, magnesium, zinc, and copper in blood and seminal plasma on semen parameters in men. Reproductive Toxicology, 2001, 15, 131-136.	1.3	171
284	Quantitative measurement of telomerase reverse transcriptase (hTERT) mRNA in urothelial cell carcinomas. International Journal of Cancer, 2000, 87, 217-220.	2.3	67
285	Early Detection of Leptomeningeal Metastasis by PCR Examination of Tumor-derived K-ras DNA in Cerebrospinal Fluid. Clinical Chemistry, 2000, 46, 132-133.	1.5	39
286	Real-Time Quantification of Human Telomerase Reverse Transcriptase mRNA in Tumors and Healthy Tissues. Clinical Chemistry, 2000, 46, 313-318.	1.5	61
287	Quantification of hTERT mRNA and Telomerase Activity in Bladder Washings of Patients with Recurrent Urothelial Cell Carcinomas. Clinical Chemistry, 2000, 46, 2003-2007.	1.5	19
288	Detection of Telomerase Activity in Urine as a Tool for Noninvasive Detection of Recurrent Bladder Tumors Is Poor and Cannot Be Improved by Timing of Sampling. Clinical Chemistry, 2000, 46, 2014-2015.	1.5	16

#	Article	IF	Citations
289	Glomerular filtration rate by single-injection inulin clearance: definition of a workable protocol for children. Annals of Clinical Biochemistry, 2000, 37, 60-66.	0.8	28
290	Use of Real-Time Quantitative PCR to Compare DNA Isolation Methods. Clinical Chemistry, 1998, 44, 2201-2204.	1.5	62
291	The Characterisation of Leukaemias with the Sysmex NE-8000. Acta Haematologica, 1997, 98, 195-198.	0.7	1
292	Studies with pre-treatment of milk with calcium acetata to reduce the phosphate content. European Journal of Pediatrics, 1995, 154, 689-689.	1.3	1
293	Exploration of the single-stranded DNA-binding domains of the gene V proteins encoded by the filamentous bacteriophages IKe and M13 by means of spin-labeled oligonucleotide and lanthanide-chelate complexes. FEBS Journal, 1993, 216, 507-517.	0.2	10
294	Improved synthesis and application of lanthanide 1,4,7,10â€tetrakis(phosphonomethyl)â€1,4,7,10â€tetraazacyclododecane complexes Ln(DOTP). Recueil Des Travaux Chimiques Des Pays-Bas, 1991, 110, 124-128.	0.0	12
295	Differences in metabolism of three low density lipoprotein subfractions in Hep G2 cells. Lipids and Lipid Metabolism, 1990, 1047, 212-222.	2.6	22
296	The relevance of a protein-enriched low density lipoprotein as a risk for coronary heart disease in relation to other known risk factors. Atherosclerosis, 1989, 77, 59-67.	0.4	37
297	Some metabolic characteristics of low-density lipoprotein subfractions, LDL-1 and LDL-2: in vitro and in vivo studies. Lipids and Lipid Metabolism, 1988, 960, 1-9.	2.6	21
298	Comparative studies on the low density lipoprotein subfractions from pig and man. Comparative Biochemistry and Physiology Part B: Comparative Biochemistry, 1988, 90, 297-300.	0.2	13